Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials

[tetano]

CPT Pharmacometrics Syst Pharmacol. 2020 Mar 20. doi: 10.1002/psp4.12510. [Epub ahead of print]
Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials.


Madelain V¹, Mentr? F¹, Baize S², Anglaret X^3,4, Laou?nan C¹, Oestereich L^5,6, Nguyen THT¹, Malvy D^3,7, Piorkowski G⁸, Graw F⁹, G?nther S^5,6, Raoul H¹⁰, de Lamballerie X⁸, Guedj J¹; Reaction! research group.

Author information




Abstract

In 2014, our research network was involved in the evaluation of favipiravir, an anti-Influenza polymerase inhibitor, against Ebola virus. In this review we discuss how mathematical modelling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a non-human primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions between the virus, the innate and adaptive immune response and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
This article is protected by copyright. All rights reserved.



PMID:32198838DOI:10.1002/psp4.12510
Free full text